FDA DEVICE FACTS
OR3O Dual Mobility System
Smith & Nephew, Inc.
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
Intended User The OR3O Dual Mobility System is intended for use in primary and revision total hip arthroplasty in skeletally mature patients. Indications
• Advanced degeneration of the hip joint as a result of degener ative, post-traumatic, or rheumatoid arthritis.
• Fracture or avascular necrosis of the femoral head.
• Failure of previous hip surgery: joint reconstruction, intern al fixation, arthrodesis, hemiarthroplasty, surface replacement arthroplasty, or total h ip replacement.
• All forms of osteoarthritis.
• Patients with hips at risk of dislocation.
• Femoral neck fracture or proximal hip joint fracture. K191002 Pa ge 2 of 6 The OR3O Dual Mobility System is intended for single use only. The modular OR3O Liners and Inserts are to be implanted without bone cement. Mating components may be indicated for use without bone cement.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。